7
Participants
Start Date
March 31, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
June 30, 2010
Bevacizumab
"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
Oxaliplatin
130 mg/m2 IV Day 1 every 21 days for eight cycles
Capecitabine
"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
Irinotecan
200 mg/m2 IV Day 1 every 21 days for eight cycles
NSABP Operations Center, Pittsburgh
Collaborators (2)
Genentech, Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY
International Drug Development Institute
OTHER
NSABP Foundation Inc
NETWORK